Navigation Links
A new drug target in atherosclerosis: The anaphylatoxin C5a
Date:1/4/2011

For decades, doctors have looked at fitness levels, weight, and overall health risk factors for heart disease and stroke. Now, they may soon add a new risk factor to the list: activation of the complement system. The complement system is usually implicated in immune responses, but now there's a role for it in cardiovascular disease. In a new research report appearing in the January 2011 print issue of the FASEB Journal (http://www.fasebj.org), scientists from Europe and the United States show that anaphylatoxin C5a, a protein released when complement is activated, contributes to atherosclerotic disease. C5a causes plaques to break free from where they would be anchored to ultimately cause blockages elsewhere in the body. This new discovery not only shows that C5a is a new marker for identifying risk for heart attack and stroke, but it also establishes C5a as a new therapeutic target for preventing these problems.

"Given the huge impact of cardiovascular disease in general, and atherosclerosis in particular, on public health, we feel that unraveling mechanisms involved in the development and progression of the disease are of utmost importance," said Johann Wojta, Ph.D., a researcher involved in the work from the University of Vienna in Austria. "Our findings have identified a particular component possibly involved in the development of atherosclerosis as a target for future therapies."

To make this discovery, Wojta and colleagues treated white blood cells with the C5a. In turn, these cells responded with the production of specific enzymes capable of dissolving the inner wall of atherosclerotic plaques in coronary or brain vessels. This causes the plaques to rupture, break free from where they are anchored, and ultimately create a blockage of the vessels, leading to the development of more serious problems such as heart attacks or strokes. The researchers also showed that C5a was present in blood vessels of patients with myocardial infarction, but not in cardiac patients without infarct. This suggests that inhibiting C5a might provide a therapeutic tool in the prevention or treatment of atherosclerosis, as well as other diseases with immune system participation such as arthritis.

"Up to now, anaphylatoxin C5a has been mainly implicated in immunologic diseases such as asthma, rheumatoid arthritis or lupus," said Gerald Weissmann, M.D., Editor-in-Chief of the FASEB Journal. "But now, this study shows that C5a, a product of an activated complement system may be responsible for the devastating effects of atherosclerosis."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. CSHL scientists identify elusive neuronal targets of deep brain stimulation
2. Delivering drugs to the brain: New research into targeted treatment of Alzheimers
3. Biodiversity targets for the future
4. Researchers discover potential genetic target for heart disease
5. TB-drugome provides new targets for anti-tuberculosis drug discovery
6. UCLA researchers discover a potential target for therapy for patients with a deadly prostate cancer
7. UNC team discovers promising target for new pancreatic cancer treatments
8. Rictor protein offers scientists a new molecular target for cancer therapies
9. Putting a bulls-eye on the flu: Paper details influenzas structure for future drug targeting
10. Link between 2 forms of ALS suggests drug target
11. New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... 2016 "Increase in mobile transactions is driving ... biometrics market is expected to grow from USD 4.03 ... at a CAGR of 29.3% between 2016 and 2022. ... growing demand for smart devices, government initiatives, and increasing ... component is expected to grow at a high rate ...
(Date:12/7/2016)... BioCatch , the global leader in behavioral biometrics, reported a ... over 40 granted and pending patents. ... , The Company,s IP portfolio expansion ... Device, and Method Estimating Force Applied to a Touch Surface, " ... components needed to estimate the force and pressure applied to touch surfaces ...
(Date:12/6/2016)... Dec. 6, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... today a five (5) year funding commitment by ... expand the rehabilitation and reentry support to more ... Established in 2004, the Prison Entrepreneurship Program (PEP) ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... , ... January 17, 2017 , ... ... re-engineered Drug Safety Technology Consortium™ (SafeTEC™), $3 million in investment towards 15+ TEC ... new tools and assays, and their applicability in drug safety assessment, for the ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... and epigenetics research, recently announced a collaboration with the Heidelberg University Hospital and ... method for library preparation, following the company’s successful launch of its CATS ...
(Date:1/17/2017)... -- On January 10 at the Medtech Showcase held in ... in San Francisco , ProclaRx CEO, ... pharmaceutical leaders and public and private investors about the ... destroy biofilms.  Biofilms are a physical ... body,s immune system from eradicating chronic infections. Infections with biofilms ...
(Date:1/16/2017)... MANHASSET, N.Y. , Jan. 16, 2017   ... Kevin J. Tracey, MD , president and CEO of ... Northwell Health, completed an analysis of how the nervous ... further identify and develop bioelectronic medicine devices ... today in Nature Neuroscience . The ...
Breaking Biology Technology: